Nanobiotix is pioneering novel nanomedicine for cancer treatment. The first-in-class product through a physical MOA aims to destroy tumors and prime the immune system for local control and systemic therapy. It is currently in clinical development in 7 indications across oncology. Listed Euronext Paris (NANO). Headquarters Paris, France. U.S affiliate Cambridge MA.